Printer Friendly

Browse Lung cancer, Non-small cell topic

Care and treatment subtopic

Articles

1-300 out of 417 article(s) nextnext page
Title Author Type Date Words
Obesity May Boost Effectiveness of a Lung Cancer Therapy. Dec 30, 2019 490
BMI, Survival Linked in NSCLC Treated With Atezolizumab; Overall, progression-free survival improved for patients with high BMI; link strongest with high PD-L1 expression. Dec 27, 2019 268
Netherlands : New lung cancer treatment conditionally included in the basic package. Dec 26, 2019 208
United States : CHMP Issues Positive Opinion to Expand CYRAMZA (ramucirumab) Label to Include Results from RELAY Study in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. Dec 16, 2019 504
United States : Data from Exploratory Analysis Show Mercks KEYTRUDA (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KRAS Mutational Status. Dec 14, 2019 434
United States : Mercks KEYTRUDA (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy. Nov 30, 2019 311
Treatment Beneficial for Nonagenarians With Lung Cancer; Most pronounced survival benefit seen for patients with stage I disease. Nov 22, 2019 269
AstraZeneca (NYSE: AZN) - Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer -- 28/10/2019. Oct 29, 2019 337
AstraZeneca reports delay in stage IV NSCLC disease progression by Imfinzi and Imfinzi plus tremelimumab in phase III POSEIDON trial. Oct 29, 2019 401
AstraZeneca reports delay in stage IV NSCLC disease progression by Imfinzi and Imfinzi plus tremelimumab in phase III POSEIDON trial. Oct 29, 2019 397
Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer; POSEIDON included both non-squamous and squamous patients and a broad choice of standard chemotherapy ... Oct 29, 2019 1868
AstraZeneca says Phase 3 POSEIDON trial in NSCLC met a primary endpoint. Oct 28, 2019 326
AstraZeneca's Triple Combo Lung Cancer Therapy Aces Late-Stage Trial. Shanthi Rexaline Oct 28, 2019 471
United States : Lilly's CYRAMZA (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology. Oct 14, 2019 456
Switzerland : First-line treatment with Tecentrik monotherapy extends survival for certain patients with advanced non-small cell lung cancer compared to chemotherapy. Oct 14, 2019 223
Merck & Company, Inc. (NYSE:MRK) - Merck's KEYTRUDA[R] (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1 -- 2/10/2019. Oct 7, 2019 540
Eli Lilly CYRAMZA data published in The Lancet Oncology. Oct 7, 2019 249
Merck's Keytruda approved as monotherapy in China for NSCLC. Oct 2, 2019 138
Bristol-Myers Squibb Shows Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo Plus Low-Dose Yervoy vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer. Oct 1, 2019 149
AstraZeneca Data Shows Tagrisso as the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years. Oct 1, 2019 580
Roche's Satralizumab Achieves Positive Phase III Results in NMOSD: Merck KGaA's tepotinib granted Breakthrough Designation in non-small cell lung cancer. Oct 1, 2019 1712
Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years. Sep 30, 2019 2054
United States : Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer. Financial report Sep 30, 2019 110
Amgen announces new data evaluating novel investigational KRAS inhibitor. Sep 29, 2019 243
Bristol-Myers announces final results from CheckMate -227 Part 1. Financial report Sep 29, 2019 283
Can Aspirin Help Tackle Some Cancers? Report Sep 23, 2019 308
ASTRO: NSAIDs May Offer Benefit to Head & Neck Cancer Patients; Benefit not significant for aspirin use in patients with non-small cell lung cancer undergoing SBRT. Sep 23, 2019 295
Merck--Pooled Analysis Continues to Show Merck's KEYTRUDA[R] (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1--10/9/2019. Sep 19, 2019 415
United States : Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients. Financial report Sep 17, 2019 396
Japan : Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Rozlytrek for ROS1-Positive NSCLC. Sep 17, 2019 349
Amgen (NASDAQ: AMGN) - Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019 -- 8/9/2019. Sep 12, 2019 483
Eli Lilly and Company UK (NYSE: LLY) - Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer -- 9/9/2019. Financial report Sep 11, 2019 806
AstraZeneca (NYSE: AZN) - Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer -- 4/9/2019. Sep 11, 2019 457
Chugai Pharmaceutical Co., Ltd. - Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Rozlytrek for ROS1-Positive NSCLC -- 6/9/2019. Sep 10, 2019 521
Amgen announces new data evaluating novel investigational KRAS inhibitor. Sep 8, 2019 210
Switzerland : Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer. Sep 7, 2019 277
European Commission approves Roche's new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer. Sep 6, 2019 333
AstraZeneca announces approval for Tagrisso in China as first-line treatment for EGFR-mutated non-small cell lung cancer. Sep 5, 2019 276
AstraZeneca announces approval for Tagrisso in China as first-line treatment for EGFR-mutated non-small cell lung cancer. Sep 5, 2019 272
Response of Leptomeningeal Metastases in EGFR-Mutated Non-Small-Cell Lung Cancer to Afatinib in the Absence of Radiotherapy. Llinas-Quintero, Nestor; Gonzalez-Hoyos, David; Yepes, Andres; Herrera, Diego A.; Pelaez-Arroyave, S Sep 1, 2019 3099
CStone & Blueprint Medicines doses first Chinese patient with BLU-667 under the global Phase I registrational study. Aug 13, 2019 257
CStone & Blueprint Medicines doses first Chinese patient with BLU-667 under the global Phase I registrational study. Aug 13, 2019 253
Severe and Fatal Multilobar Nonclassic Radiation Pneumonitis following Stereotactic Body Radiation Therapy (SBRT) for Treatment of Inoperable Non-Small-Cell Lung Cancer: A Report of Two Cases and Possible Enhancement by Concurrent Amiodarone. Georgiou, Anastasios; Farmer, Adam Aug 1, 2019 3413
Emerging Risk Profile of Lung Cancer Therapy: Diffuse Alveolar Hemorrhage from Osimertinib. Forte, Michael J.; Sangani, Rahul G. Aug 1, 2019 2686
Genprex Inc initiates first phase of branding for its lead drug candidate, Oncoprex immunogene therapy. Jul 31, 2019 515
Genprex Inc initiates first phase of branding for its lead drug candidate, Oncoprex immunogene therapy. Jul 31, 2019 515
Switzerland : Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer. Jul 30, 2019 165
Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer. Jul 26, 2019 268
Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors. Jul 16, 2019 1007
Calithera initiates Phase 1/2 trial of telaglenastat with Pfizer's palbociclib. Jul 2, 2019 157
Jounce Therapeutics initiates Phase 2 EMERGE study of vopratelimab. Jun 18, 2019 234
United Kingdom : Imfinzi is the only immunotherapy to demonstrate overall survival at three years in unresectable Stage III non-small cell lung cancer. Jun 12, 2019 478
Radiation elevates cardiac risk in lung cancer patients: Study. Jun 11, 2019 415
Sotio's DCVAC/LuCa Significantly Improves Survival in Patients with Stage IV Non-small Cell Lung Cancer. Jun 4, 2019 255
AstraZeneca Touts Imfinzi is the Only Immunotherapy to Demonstrate Overall Survival at Three Years in Unresectable, Stage III Non-Small Cell Lung Cancer. Jun 4, 2019 768
Five-Year Survival Data for US Merck's Keytruda in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting. Jun 3, 2019 679
Blueprint Medicines announces new data from ARROW trial of BLU-667. Jun 3, 2019 138
Merck says Keytruda demonstrated five-year overall survival rate of 23.2%. Jun 2, 2019 234
Immunotherapy boosts survival outlook for lung cancer patients: study. Jun 2, 2019 351
United States : European Commission Approves Lorviqua (Lorlatinib) for Certain Adult Patients With Previously-treated Alk-positive Advanced Non-small Cell Lung Cancer. May 11, 2019 567
Kucuk Hucreli Disi Akciger Kanserinde ALK Geninin Yeniden Duzenlenmesinin FISH Yontemi ile Belirlenmesi/Determination of ALK Gene Rearrangment with FISH Method in Non Small Cell Lung Carcinoma. Seymen, Pelin Nimet; Gumuslu, Esen Report May 7, 2019 3166
Bristol-Myers Squibb Releases Long-Term Survival Results from Pooled Analyses of Opdivo in Previously-Treated Non-Small Cell Lung Cancer Patients. Apr 5, 2019 107
Norway : Bergenbio Extends Phase Ii Trial With Bemcentinib and Keytruda in Nsclc to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy. Apr 5, 2019 206
Bristol-Myers reports long-term survival results from pooled analyses of Opdivo. Financial report Apr 2, 2019 296
Merck's KEYTRUDA approved in China for treatment of NSCLC. Apr 1, 2019 136
European Commission Approves US Merck's Keytruda (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer. Mar 15, 2019 497
Switzerland : Helsinn initiates two new global Phase III studies with anamorelin. Mar 11, 2019 403
Switzerland : European Commission approves Roches Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer. Mar 9, 2019 223
Pfizer Receives Positive CHMP Opinion for Lorviqua for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer. Mar 4, 2019 444
Prospective comparative study of pemetrexed and carboplatin versus paclitaxel and carboplatin as first-line chemotherapy in adenocarcinoma lung. Das, Tapas Kumar; Das, Pabitra; Das, Sunita; Jana, Arpan Report Mar 1, 2019 3588
Switzerland : FDA grants Priority Review to Roches personalised medicine entrectinib. Feb 23, 2019 390
Advaxis Enrolls First Patient in its Phase 1/2 Trial for ADXS-HOT in the Treatment of Non-Small Cell Lung Cancer. Feb 19, 2019 413
Advaxis enrolls first patient in Phase 1/2 trial for ADXS-HOT. Feb 14, 2019 154
Biocept announces publication of a peer-reviewed article on ctDNA testing. Feb 5, 2019 112
European Medicines Agency Adopts Positive Opinion for US Merck's Keytruda in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC). Feb 4, 2019 430
Pfizer receives positive CHMP opinion for Vizimpro. Feb 1, 2019 214
Rutgers Cancer Institute researcher receives American Lung Association grant. Perry, Jessica Brief article Jan 24, 2019 177
Roche PH launches immunotherapy for previously treated non-small cell lung cancer. Dec 6, 2018 577
The Apoptotic and Anti-apoptotic Effects of Pendimethalin and Trifluralin on A549 Cells In Vitro/Pendimetalin ve Trifluralinin Apopitotik ve Anti-Apopitotik Etkilerinin A549 Hucrelerinde In Vitro Degerlendirilmesi. Sarigol-Kilic, Zehra; Undeger-Bucurgat, Ulku Report Dec 1, 2018 3913
European Commission Approves Alunbrig for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe. Nov 28, 2018 351
Roche (Philippines) Inc. launches immunotherapy for previously treated non-small cell lung cancer. Nov 26, 2018 610
Tesaro reports initial data from AMBER trial of TSR-022, TSR-042 combo. Nov 9, 2018 320
United States : Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden ?10 mut/Mb. Nov 6, 2018 125
Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. Monroig-Bosque, Paloma del C.; Driver, Brandon; Morales-Rosado, Joel A.; Deavers, Michael; Tacha, Da Report Nov 1, 2018 4002
Morgan Stanley downgrades Syndax to Equal Weight after breast cancer study miss. Oct 29, 2018 122
Switzerland : Roches Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer. Oct 25, 2018 633
Switzerland : Roches Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone. Oct 25, 2018 133
Genentech's Tecentriq Plus Chemotherapy (Carboplatin and Abraxane) as an Initial Treatment Helped People With Advanced Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy Alone. Oct 24, 2018 183
Thermal Ablation Acceptable for Early Lung Cancer; Regarding overall survival, thermal ablation non-inferior to radiation for primary treatment. Oct 23, 2018 212
Genentech Tecentriq plus chemo as initial treatment helped people with NSCLC. Oct 22, 2018 109
Novartis: Phase II Geometry data shows ORR of 72%, 39.1% in study. Oct 19, 2018 214
Incyte: Phase II Geometry data shows ORR of 72%, 39.1% in study. Oct 19, 2018 162
Guardant Health announces results froom NSCLC study. Clinical report Oct 16, 2018 102
BerGenBio Enters Second Stage of Phase II Trial with Selective AXL Inhibitor bemcentinib in Combination with US Merck's Keytruda in Patients with Advanced NSCLC. Oct 8, 2018 587
Role of Recursive Partitioning Analysis and Graded Prognostic Assessment on Identifying Non-Small Cell Lung Cancer Patients with Brain Metastases Who May Benefit from Postradiation Systemic Therapy. Liu, Shuai; Chen, Peng; Liu, Yan-Wei; Gu, Xue-Nan; Qiu, Xiao-Guang; Li, Bo Report Oct 1, 2018 4742
United Kingdom : European Commission approves Imfinzi for locally-advanced, unresectable NSCLC. Sep 26, 2018 684
Genentech's Tecentriq in Combination with Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in a Type of Previously Untreated Advanced Lung Cancer. Sep 25, 2018 140
Loxo Oncology announces LOXO-292 durability update. Sep 25, 2018 123
Genentech: Tecentriq + chemotherapy reduced risk of disease worsening in trial. Sep 24, 2018 180
Takeda Receives Positive CHMP Opinion Recommending Alunbrig (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib. Sep 24, 2018 1082
Takeda Pharmaceutical receives positive CHMP opinion recommending Alunbrig. Sep 21, 2018 289
Spectrum expands poziotinib trial into first-line therapy, doses first patient. Sep 12, 2018 321
European Commission Approves Merck's Keytruda in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALKGenomic Tumor Aberrations. Sep 10, 2018 170
Merck: EC approves KEYTRUDA in combination with pemetrexed. Sep 10, 2018 108
FDA grants breakthrough designation to Loxo Oncology's LOXO-292. Sep 5, 2018 225
FDA grants breakthrough designation to Loxo Oncology's LOXO-292. Sep 5, 2018 221
Loxo Oncology announces breakthrough therapy designation for LOXO-292 from FDA. Sep 5, 2018 114
Prognostic analysis of surgical-pathologic N1 disease in non-small cell lung cancer: Single-center experience with 276 cases. Yazgan, Serkan; Ucvet, Ahmet; Gursoy, Soner; Samancilar, Ozgur; Guvenc, Ezgi Cimen Sep 1, 2018 3728
United Kingdom : Tagrisso approved in Japan for 1st-line treatment of EGFR-mutated non-small cell lung cancer. Aug 23, 2018 342
AstraZeneca reports approval for Tagrisso in Japan for 1st-line NSCLC. Aug 22, 2018 240
AstraZeneca reports approval for Tagrisso in Japan for 1st-line NSCLC. Aug 22, 2018 236
AstraZeneca announces Japanese approval of Tagrisso for first-line NSCLC. Aug 21, 2018 136
Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer. Dong, Jie; Wang, Xu; Yu, Yu; Yan, Xu; Cui, Jiu-Wei Report Aug 20, 2018 3710
MiR-125b-1-3p Exerts Antitumor Functions in Lung Carcinoma Cells by Targeting S1PR1. Zhang, Xiang; Liu, Yu; Huang, Wei-Cong; Zheng, Liang-Cheng Report Aug 20, 2018 4074
Germany : Boehringer Ingelheim completes enrolment of GioTag real-world study. Aug 13, 2018 425
JHL Biotech announces positive CHMP Scientific Advice for proposed JHL1149 bevacizumab biosimilar for lung cancer. Aug 10, 2018 219
JHL Biotech announces positive CHMP Scientific Advice for proposed JHL1149 bevacizumab biosimilar for lung cancer. Aug 10, 2018 215
Foundation Medicine publishes new data in Nature Medicine on bTMB. Aug 6, 2018 357
Genentech's Tecentriq in Combination with Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with Advanced Lung Cancer. Aug 2, 2018 305
Comparison of the Effects of the Sixth and Seventh TNM Staging on Survival in Operable Non-Small Cell Lung Cancer. Kuzucuoglu, Mustafa; Karamustafaoglu, Yekta Altemur; Yoruk, Yener Aug 1, 2018 3051
BeiGene announces first patient dosed in Phase 3 trial of tislelizumab. Jul 24, 2018 109
United States : Selective AXL Inhibitor Bemcentinib meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With Keytruda. Jul 2, 2018 354
Cell-Free DNA Utility and Value of Recommendation. Levy, Benjamin Report Jul 1, 2018 1850
Molecular Testing in Lung Cancer: Where to Draw the Line? Halmos, Balazs Report Jul 1, 2018 2487
Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients With Targetable Mutations Following Disease Progression. Saxena, Ashish Report Jul 1, 2018 1764
Bristol-Myers announces CNDA approval of Opdivo for NSCLC treatment. Jun 15, 2018 160
United States : Mercks KEYTRUDA (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival in First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in Phase 3 KEYNOTE-407 Study. Report Jun 13, 2018 280
United States : KEYTRUDA (pembrolizumab) Monotherapy Significantly Improved Overall Survival in KEYNOTE-042 Study as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-L1 (TPS ?1%). Report Jun 13, 2018 415
KEYNOTE-042 Phase 3 Study of Keytruda as First-Line Treatment for Locally Advanced or Metastatic NSCLC Patients Whose Tumors Expressed PD-L1 Yields Positive Results. Report Jun 7, 2018 344
Genentech's Tecentriq Plus Chemotherapy Decreases the Risk of Disease Worsening or Death for People with Advanced Squamous Non-Small Cell Lung Cancer in Phase III IMpower131 Study. Jun 7, 2018 282
Phase 3 KEYNOTE-407 Study of Keytruda Plus Chemotherapy Shows Increased Overall Survival in First-Line Treatment of Metastatic Squamous NSCLC. Report Jun 7, 2018 325
Aduro Biotech announces initiation of Phase 1b study of ADU-214 for lung cancer. Jun 7, 2018 131
Switzerland : Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer. Jun 5, 2018 282
Merck's KEYTRUDA 'significantly improved' overall survival in KEYNOTE-042 study. Report Jun 3, 2018 220
KEYTRUDA plus chemotherapy 'significantly improved' OS in Phase 3 KEYNOTE-407. Jun 3, 2018 259
Janssen to withdraw phase Ib/II study of daratumumab in combination with atezolizumab. May 29, 2018 185
Merck's Keytruda Demonstrates Improved Survival Benefit as First-Line Treatment in Advanced NSCLC. Clinical report May 29, 2018 295
Janssen to withdraw phase Ib/II study of daratumumab in combination with atezolizumab. May 29, 2018 181
United States : Mercks KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial. May 29, 2018 230
Genmab reports stopping of studies of Daratumumab in combination with anti-PD-(L)1 by Janssen. May 28, 2018 389
Genmab reports stopping of studies of Daratumumab in combination with anti-PD-(L)1 by Janssen. May 28, 2018 390
Genmab reports stopping of studies of Daratumumab in combination with anti-PD-(L)1 by Janssen. May 28, 2018 385
Switzerland : Phase III IMpower150 study showed Roches Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel. May 18, 2018 480
New biomarker found for early diagnosis of lung cancer. May 9, 2018 274
Health Canada approves AstraZeneca's Imfinzi for stage III, unresectable lung cancer. May 9, 2018 169
Health Canada approves AstraZeneca's Imfinzi for stage III, unresectable lung cancer. May 9, 2018 165
Bristol-Myers Squibb Receives EMA Validation of Application for Opdivo Plus Yervoy Combination for Treatment of NSCLC. May 8, 2018 152
Merck Trial of Keytruda Combination for Treatment of sNSCLC Meets Secondary Endpoint of ORR at Interim Analysis. Clinical report May 8, 2018 326
Personal Genome Diagnostics Whole Exome Analysis of TMB Helps Identify NSCLC Patients Likely to Benefit from Immuno-Oncology Treatment Before Surgery. Apr 23, 2018 234
Merck rises, Bristol-Myers slides following cancer meeting. Apr 16, 2018 270
Goldman says Bristol-Myers reaction to NSCLC data, Merck news 'way overdone'. Apr 16, 2018 504
Merck's Keytruda as Monotherapy Significantly Improves Overall Survival as First-Line Therapy in NSCLC Patients Expressing PD-L1 in at Least 1% of Tumor Cells. Apr 11, 2018 378
BerGenBio concludes recruitment under first stage of Phase II NSCLC trial of bemcentinib in combination with KEYTRUDA. Apr 10, 2018 273
BerGenBio concludes recruitment under first stage of Phase II NSCLC trial of bemcentinib in combination with KEYTRUDA. Apr 10, 2018 269
Merck: Phase 3 KEYNOTE-042 trial met primary endpoint of overall survival. Apr 9, 2018 188
Pfizer: FDA, EMA accept regulatory submissions for dacomitinib review. Apr 4, 2018 239
Clinically Significant Dysregulation of hsa-miR-30d-5p and hsa-let-7b Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer. Hosseini, Sayed Mostafa; Soltani, Bahram Mohammad; Tavallaei, Mahmoud; Mowla, Seyed Javad; Tafsiri, Apr 1, 2018 4541
Armo BioSciences enrolls first patient in CYPRESS 2 trial. Clinical report Mar 29, 2018 252
Genentech's Tecentriq (Atezolizumab) Plus Chemotherapy Achieves PFS in Initial Treatment of Advanced Squamous NSCLC. Mar 22, 2018 314
Switzerland : Phase III IMpower131 study showed Roches TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced squamous lung cancer. Mar 20, 2018 268
Japan : Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer. Feb 24, 2018 275
Hutchison China MediTech completes patient enrollment in Phase III FALUCA trial. Feb 13, 2018 134
Pfizer announces FDA acceptance of NDA for lorlatinib. Feb 12, 2018 200
Japan : Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. Feb 8, 2018 352
BeiGene initiates global Phase 3 trial of tislelizumab. Jan 31, 2018 185
Japan : Chugai Obtains Approval of Humanized Anti-PD-L1 Monoclonal Antibody, TECENTRIQ Intravenous Infusion 1200mg for the Treatment of Unresectable, Advanced or Recurrent Non-small Cell Lung Cancer. Jan 20, 2018 370
Amgen and Allergan's Mvasi for certain cancers approved in Europe. Jan 18, 2018 114
Canada,United States : Mercks KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-S. Jan 17, 2018 207
Canada,United States : Mercks KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-S. Jan 17, 2018 209
Canada,United States : Mercks KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-S. Jan 17, 2018 209
Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer. Yang, R.F.; Yu, B.; Zhang, R.Q.; Wang, X.H.; Li, C.; Wang, P.; Zhang, Y.; Han, B.; Gao, X.X.; Zhang, Report Jan 1, 2018 5456
Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome. Chaucer, Benjamin; Stone, Abriella; Demanes, Augustus; Seibert, Shawn M. Jan 1, 2018 1500
Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab. Nakayama, Shingo; Sasaki, Mamoru; Morinaga, Shojiroh; Minematsu, Naoto Jan 1, 2018 1762
Traditional Chinese Medicine Integrated with Chemotherapy for Stage II-IIIA Patients with Non-Small-Cell Lung Cancer after Radical Surgery: A Retrospective Clinical Analysis with Small Sample Size. Zhao, Xueyu; Dai, Xiaojun; Wang, Shanshan; Yang, Ting; Yan, Yan; Zhu, Guang; Feng, Jun; Pan, Bo; Sun Jan 1, 2018 4468
Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience. Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Morris, John C. Morris; Karim, Nagla Abdel Disease/Disorder overview Jan 1, 2018 3229
France : Promising clinical results for innovative mutated anti-EGFR radiotracer in patients with non-small cell lung cancer. Dec 23, 2017 344
Roche's combination of Tecentriq and Avastin plus chemotherapy extends lung cancer patients' lives in Phase III study. Dec 11, 2017 178
Roche's combination of Tecentriq and Avastin plus chemotherapy extends lung cancer patients' lives in Phase III study. Dec 11, 2017 182
Comparative Evaluation of Mediastinal Lymph Nodes in Non-small Cell Lung Cancer with Computed Tomography, 99mTc-MIBI SPECT, and Video-Mediastinoscopy. Onal, Omer; Demir, Omer Faruk Clinical report Dec 1, 2017 3991
Evaluation of Prognostic Factors for Survival in Stage I Non-small Cell Lung Carcinoma. Gurler, Fatih; Onal, Omer; Demir, Omer Faruk Dec 1, 2017 3876
United Kingdom : AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan. Nov 28, 2017 115
AstraZeneca submits sNDA for Tagrisso in Japan. Nov 27, 2017 217
AstraZeneca submits sNDA for Tagrisso in Japan. Nov 27, 2017 213
Switzerland : Phase III IMpower150 study showed Roches TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer. Nov 21, 2017 243
United States : Phase III IMpower150 Study Showed Genentechs Tecentriq (Atezolizumab) and Avastin (Bevacizumab) Plus Chemotherapy Significantly Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People with a Type of Advanced Lung. Nov 20, 2017 249
Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population. Tezel, Gaye Guler; Sener, Ebru; Aydin, Cisel; Onder, Sevgen Nov 1, 2017 3095
Merck says Keytruda more than doubled median overall survival of study patients. Oct 18, 2017 151
United States : Thermo Fisher Scientific's Oncomine Dx Target Test for Non-Small Cell Lung Cancer Receives Coverage from First Regional Health Plan. Oct 17, 2017 324
Switzerland : CHMP recommends EU approval of Roches Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC. Oct 14, 2017 128
EMA accepts MAA for Imfinzi in locally-advanced unresectable non-small cell lung cancer. Oct 9, 2017 181
United States : Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Sep 11, 2017 409
United Kingdom : Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine to show superior PFS in this setting. Sep 11, 2017 301
United States : Mercks KEYTRUDA (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in Patients with First-Line Nonsquamous NSCLC. Sep 11, 2017 956
Thermal Ablation in the Management of Adrenal Metastasis Originating from Non-small Cell Lung Cancer: A 5-year Single-center Experience. Botsa, Evanthia; Thanou, Ioanna; Papatheodoropoulou, Aspasia; Thanos, Loukas Report Sep 1, 2017 3228
Ready to Settle. Shajani-Yi, Zahra; Brunelle, Abigail A.; Nerenz, Robert D. Clinical report Sep 1, 2017 476
Australia : New treatment for lung and kidney cancer on PBS. Aug 2, 2017 353
United States : Imfinzi granted Breakthrough Therapy Designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer. Aug 2, 2017 371
AstraZeneca granted Breakthrough Therapy Designation by FDA for Imfinzi. Jul 31, 2017 211
AstraZeneca granted Breakthrough Therapy Designation by FDA for Imfinzi. Jul 31, 2017 207
Astrazeneca's Phase III FLAURA trial shows strong result for Tagrisso in lung cancer. Jul 28, 2017 277
Astrazeneca's Phase III FLAURA trial shows strong result for Tagrisso in lung cancer. Jul 28, 2017 273
United States : Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin1 (bevacizumab). Jul 26, 2017 223
The European Commission approves Novartis' Zykadi for lung cancer. Jul 3, 2017 164
The European Commission approves Novartis' Zykadi for lung cancer. Jul 3, 2017 160
Combining two different chemotherapy agents with platinum analogs as induction and consolidation regimes in nonsmall cell lung carcinoma. Khan, Mohsin; Siddiqui, Shahid Report Jul 1, 2017 2309
EC approves first-line use of Novartis' Zykadia in ALK-positive advanced non-small cell lung cancer. Jun 29, 2017 231
Thermo Fisher receives US FDA premarket approval for its Oncomine Dx Target Test for non-small cell lung cancer detection. Jun 23, 2017 278
Rapid biomarker testing for improved clinical decision-making in non-small cell lung cancer. Kaplan, Edward H. Cover story Jun 1, 2017 3817
AstraZeneca decreases risk of worsening or death in patients with third stage lung cancer in phase three trial of Imfinzi. May 16, 2017 236
AstraZeneca decreases risk of worsening or death in patients with third stage lung cancer in phase three trial of Imfinzi. May 16, 2017 232
United States : Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003. Report Apr 4, 2017 353
United States : Phase III ALUR study supports the use of Roches Alecensa for people with advanced ALK-positive lung cancer. Apr 4, 2017 332
Novartis receives EU approval for expansion of use of Tafinlar/Mekinist combination. Apr 3, 2017 243
Novartis receives EU approval for expansion of use of Tafinlar/Mekinist combination. Apr 3, 2017 239
A Model Predicting Lymph Node Status for Patients with Clinical Stage T1aN0-2M0 Nonsmall Cell Lung Cancer. Zang, Ruo-Chuan; Qiu, Bin; Gao, Shu-Geng; He, Jie Report Apr 1, 2017 4345
Spectrum Pharmaceuticals Launches Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. Mar 31, 2017 292
Sublobar resection for clinical stage I nonsmall cell lung cancers. Huang, Tsai-Wang; Chen, Yi-Hsi; Huang, Kai-Hsu; Chang, Hung; Lee, Shih-Chun Report Mar 1, 2017 3350
European Medicines Agency committee recommends approval of Novartis's Tafinlar in combination with Mekinist. Feb 28, 2017 228
European Medicines Agency committee recommends approval of Novartis's Tafinlar in combination with Mekinist. Feb 28, 2017 224
Novartis receives positive CHMP opinion for Tafinlar and Mekinist combination in lung cancer. Feb 27, 2017 221
Novartis receives positive CHMP opinion for Tafinlar and Mekinist combination in lung cancer. Feb 27, 2017 217
Novartis drug Zykadia granted FDA Priority Review. Feb 24, 2017 256
Novartis drug Zykadia granted FDA Priority Review. Feb 24, 2017 252
EC Approves US Merck's Keytruda for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer When Tumors Have High PD-L1 Expression with No EGFR or ALK Positive Tumor Mutations. Feb 1, 2017 332
Agilent Technologies Expands Dako PD-L1 IHC 22C3 PharmDx Companion Diagnostics. Feb 1, 2017 371
Merck submits sBLA for KEYTRUDA with the US FDA for the treatment of patients with advanced non-small cell lung cancer. Jan 11, 2017 326
Merck submits sBLA for KEYTRUDA with the US FDA for the treatment of patients with advanced non-small cell lung cancer. Jan 11, 2017 322
Apoptosis of Lewis Lung Carcinoma Cells Induced by Microwave via p53 and Proapoptotic Proteins In vivo. Zhang, Kou-Dong; Tong, Lin-Rong; Wang, Shui-Ming; Peng, Rui-Yun; Huang, Hai-Dong; Dong, Yu-Chao; Zha Report Jan 1, 2017 4677
Shenfu Injection Adjunct with Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review. Cao, Ailing; He, Hailang; Jing, Mengxin; Yu, Beibei; Zhou, Xianmei Report Jan 1, 2017 10087
Yin-Cold or Yang-Heat Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept. Zhu, Yan-juan; Zhang, Hai-bo; Liu, Li-rong; Liu, Yi-hong; Zhang, Fu-li; Bai, Jian-ping; Li, Yong; Qu Jan 1, 2017 5259
Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy. Huang, Bao-Tian; Zhang, Wu-Zhe; Wu, Li-Li; Lin, Pei-Xian; Lu, Jia-Yang Report Jan 1, 2017 5838
Diagnostic MicroRNA Biomarker Discovery for Non-Small-Cell Lung Cancer Adenocarcinoma by Integrative Bioinformatics Analysis. Shao, Yang; Liang, Bin; Long, Fei; Jiang, Shu-Juan Report Jan 1, 2017 4728
Multislice Analysis of Blood Flow Values in CT Perfusion Studies of Lung Cancer. Malavasi, Silvia; Barone, Domenico; Gavelli, Giampaolo; Bevilacqua, Alessandro Report Jan 1, 2017 8252
Tissue Factor Pathway Inhibitor-1 Is a Valuable Marker for the Prediction of Deep Venous Thrombosis and Tumor Metastasis in Patients with Lung Cancer. Fei, Xianming; Wang, Huan; Yuan, Wufeng; Wo, Mingyi; Jiang, Lei Report Jan 1, 2017 4966
A Dosimetric Comparison of Dose Escalation with Simultaneous Integrated Boost for Locally Advanced Non-Small-Cell Lung Cancer. Yang, Wenjuan; Zeng, Biao; Qiu, Yanfang; Tan, Jianfeng; Xu, Shilei; Cai, Yilong; Zhou, Yujuan; Liu, Clinical report Jan 1, 2017 4157
Acute "Pseudoischemic" ECG Abnormalities after Right Pneumonectomy. Vasic, Nada; Dimic-Janjic, Sanja; Stevic, Ruza; Milenkovic, Branislava; Djukanovic, Verica Case study Jan 1, 2017 2176
Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation? Joshi, Amit; Noronha, Vanita; Patil, Vijay M.; Chougule, Anuradha; Bhattacharjee, Atanu; Kumar, Raji Jan 1, 2017 2478
A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment. Chubachi, Shotaro; Yasuda, Hiroyuki; Irie, Hidehiro; Fukunaga, Koichi; Naoki, Katsuhiko; Soejima, Ke Clinical report Jan 1, 2017 1221
Merck's KEYTRUDA(R) (pembrolizumab) gains Japanese approval. Dec 20, 2016 214
Merck's KEYTRUDA(R) (pembrolizumab) gains Japanese approval. Dec 20, 2016 210
Merck receives positive recommendation for KEYTRUDA for treating metastatic non-small cell lung cancer in adults. Dec 19, 2016 311
Merck receives positive recommendation for KEYTRUDA for treating metastatic non-small cell lung cancer in adults. Dec 19, 2016 307
Germany : New European study highlights differing priorities in physicians therapy goals when treating advanced lung cancer patients. Nov 9, 2016 573
United States : Defining the true value of innovation in cancer treatment. Oct 21, 2016 370
United States : Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer. Oct 10, 2016 146
Japan : Chugais Alecensa Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer. Oct 7, 2016 463
Trifolin induces apoptosis via extrinsic and intrinsic pathways in the NCI-H460 human non-small cell lung-cancer cell line. Kim, Min-Je; Kwon, Sae-Bom; Kim, Man-Sub; Jin, Seung Won; Ryu, Hyung Won; Oh, Sei-Ryang; Yoon, Do-Yo Report Sep 15, 2016 4017
United States : Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss. Sep 10, 2016 466
Brain Radiotherapy Doesn't Help Lung Cancer Patients. Sep 6, 2016 415
Pfizer passes EC approval for XALKORI (crizotinib) for the treatment of ROS1-positive advanced non-small cell lung cancer. Sep 1, 2016 266
Pfizer passes EC approval for XALKORI (crizotinib) for the treatment of ROS1-positive advanced non-small cell lung cancer. Sep 1, 2016 262
United States : XALKORI (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer. Sep 1, 2016 437
ARIAD Pharmaceuticals concludes rolling submission of Brigatinib's NDA with US FDA for non-small cell lung cancer. Aug 31, 2016 256
ARIAD Pharmaceuticals concludes rolling submission of Brigatinib's NDA with US FDA for non-small cell lung cancer. Aug 31, 2016 252
AstraZeneca fails to meet selumetinib's main goal in phase III trial for lung cancer. Aug 10, 2016 157
AstraZeneca fails to meet selumetinib's main goal in phase III trial for lung cancer. Aug 10, 2016 153
United States : Mercks KEYTRUDA (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1. Aug 3, 2016 270
Merck passes European Commission approval for KEYTRUDA to treat NSCLC patients. Aug 3, 2016 280
Merck passes European Commission approval for KEYTRUDA to treat NSCLC patients. Aug 3, 2016 276
First-Line Immune Therapy--Implications for Pathologists. Miller, Ross A.; Cagle, Philip T.; Bernicker, Eric H. Aug 1, 2016 1199
Merck receives positive opinion recommending EU approval of KEYTRUDA for treatment of NSCLC. Jun 27, 2016 257
Switzerland : Novartis pivotal data for Tafinlar + Mekinist demonstrated a 63 percent overall response rate in treating rare form of lung cancer. Jun 7, 2016 552
Merck's KEYTRUDA (pembrolizumab), an anti-PD-1 therapy for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL), has been granted Breakthrough Therapy Designation by the FDA. Jun 1, 2016 115
Biocept unveils proprietary liquid biopsy test to detect RET fusions in lung cancer patients. May 19, 2016 222
Biocept unveils proprietary liquid biopsy test to detect RET fusions in lung cancer patients. May 19, 2016 218
Boehmenan, a lignan from the Chinese medicinal plant Clematis armandii, induces apoptosis in lung cancer cells through modulation of EGF-dependent pathways. Pan, Li-Long; Wang, Xi-Ling; Zhang, Qiu-Yang; Luo, Xiao-Ling; Xu, Peng; Liu, Si-Yu; Hu, Jin-Feng; Li Report May 15, 2016 5283
Crown Bioscience publishes establishment and characterisation of NSLCL patient-derived xenograft models. May 12, 2016 200
Crown Bioscience publishes establishment and characterisation of NSLCL patient-derived xenograft models. May 12, 2016 196
Merck passes conditional approval for KEYTRUDA for the treatment of metastatic non-small cell lung cancer (NSCLC) in Canada. Apr 21, 2016 360
Merck passes conditional approval for KEYTRUDA for the treatment of metastatic non-small cell lung cancer (NSCLC) in Canada. Apr 21, 2016 356
Clovis Oncology's NDA for Rociletinib to be reviewed by the US FDA for non-small cell lung cancer. Apr 13, 2016 200
Clovis Oncology's NDA for Rociletinib to be reviewed by the US FDA for non-small cell lung cancer. Apr 13, 2016 196
Boheringer Ingelheim's Giotrif (afatinib) gains European approval as treatment option for squamous cell lung carcinoma. Apr 8, 2016 232
Boheringer Ingelheim's Giotrif (afatinib) gains European approval as treatment option for squamous cell lung carcinoma. Apr 8, 2016 228
Germany : Giotrif (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung. Apr 8, 2016 485
United States : AstraZeneca to showcase clinical and scientific leadership in lung cancer at ELCC 2016. Apr 7, 2016 661
Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Sholl, Lynette M.; Aisner, Dara L.; Allen, Timothy Craig; Beasley, Mary Beth; Borczuk, Alain C.; Cag Apr 1, 2016 3349
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe? Kerr, Keith M.; Hirsch, Fred R. Apr 1, 2016 5823
United States : Tagrisso (osimertinib) approved in Japan for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Mar 30, 2016 496
United States : XALKORI Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer. Mar 14, 2016 514
United States : FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer. Mar 12, 2016 618
Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective. Bernicker, Eric Mar 1, 2016 4172
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. Kerr, Keith M.; Nicolson, Marianne C. Mar 1, 2016 5316
United Kingdom : TAGRISSO (osimertinib) approved in EU as first-in-class treatment for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Feb 4, 2016 659
Delaying chemotherapy in the treatment of stage IV non-small cell lung cancer does not adversely affect survival outcome. Mozayen, Mohammad; Alsharedi, Mohamed; Mehmi, Inderjit; Gress, Todd; Tirona, Maria Tria Report Jan 1, 2016 2424
United States : TAGRISSO (osimertinib) receives positive CHMP opinion for patients with EGFR T790M mutation-positive metastatic non-small cell lung cancer. Dec 19, 2015 553
Adaptimmune Therapeutics starts study of affinity enhanced T-cell therapy. Nov 26, 2015 170
Adaptimmune Therapeutics starts study of affinity enhanced T-cell therapy. Nov 26, 2015 166
Pfizer passes approval in Europe to expand use of XALKORI to first-line treatment of adults with ALK positive advanced non-small cell lung cancer. Nov 25, 2015 285
Pfizer passes approval in Europe to expand use of XALKORI to first-line treatment of adults with ALK positive advanced non-small cell lung cancer. Nov 25, 2015 281
United States : Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Smal. Nov 19, 2015 349
Germany : Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer. Clinical report Nov 5, 2015 459
Postoperative Regulatory T-Cells and Natural Killer Cells in Stage I Nonsmall Cell Lung Cancer Underwent Video-assisted Thoracoscopic Lobectomy or Thoracotomy. Zhang, Sai; Pan, Sai-Bo; Lyu, Qing-Hua; Wu, Pin; Qin, Guang-Ming; Wang, Qi; He, Zhong-Liang; He, Xue Report Nov 1, 2015 4571
Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III non-small cell lung cancer. Report Oct 31, 2015 3078
Correlation between expression of epidermal growth factor receptor and adverse reactions after chemotherapy of advanced non-small-cell lung cancer. Oct 31, 2015 3767
A Matched Comparison Study of Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early-stage Nonsmall Cell Lung Cancer. Mu, Ju-Wei; Gao, Shu-Geng; Xue, Qi; Zhao, Jun; Li, Ning; Yang, Kun; Su, Kai; Yuan, Zhu-Yang; He, Jie Report Oct 20, 2015 3191
United States : FDA expands approved use of Opdivo in advanced lung cancer. Oct 10, 2015 763
Percent of nonsmoker lung cancer patients rises. London, Susan Oct 1, 2015 857
United States : MERK, SYNDAX PHARMA announce dosing of first patients in Entinostat Phase 1b/2 clinical test. Oct 1, 2015 276
Clovis Oncology announces two major regulatory milestones for its investigational therapy rociletinib for the treatment of patients with NSCLC. Sep 30, 2015 252

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters